ACE2 activation has vasodilator properties, and as such a loss of ACE2expression and function could lead to the development of hypertension.16 Although not conclusively shown, it is possible that RAS inhibition enhances tissueACE2 expression and function, and ACE2 upregulation by ACEIs/ARBs might explain the survivalbenefit associated with their use is patients with hypertension and concurrent COVID-19 infection.16 Sama et al17 recently showed a reduction in plasma ACE2 levels in a large number of heart failurepatients receiving ACEIs/ARBs. This evidence concerns the gene ACE2 and hypertensive disorder.